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ORIGINAL ARTICLE
Population Pharmacokinetics of Bedaquiline and
Metabolite M2 in Patients With Drug-Resistant
Tuberculosis: The Effect of Time-Varying
Weight and Albumin
EM Svensson*, A-G Dosne and MO Karlsson
Albumin concentration and body weight are altered in patients with multidrug-resistant tuberculosis (MDR-TB) and change
during the long treatment period, potentially affecting drug disposition. We here describe the pharmacokinetics (PKs) of the
novel anti-TB drug bedaquiline and its metabolite M2 in 335 patients with MDR-TB receiving 24 weeks of bedaquiline on top of
a longer individualized background regimen. Semiphysiological models were developed to characterize the changes in weight
and albumin over time. Bedaquiline and M2 disposition were well described by three and one-compartment models,
respectively. Weight and albumin were correlated, typically increasing after the start of treatment, and significantly affected
bedaquiline and M2 plasma disposition. Additionally, age and race were significant covariates, whereas concomitant human
immunodeficiency virus (HIV) infection, sex, or having extensively drug-resistant TB was not. This is the first population
model simultaneously characterizing bedaquiline and M2 PKs in its intended use population. The developed model will be
used for efficacy and safety exposure-response analyses.
CPT Pharmacometrics Syst. Pharmacol. (2016) 5, 682–691; doi:10.1002/psp4.12147; published online 8 November 2016.
Study Highlights
WHAT ISTHECURRENTKNOWLEDGEONTHETOPIC?
 Population PKs of bedaquiline, a highly protein bound
anti-TB drug, has previously been described.
WHAT QUESTION DID THIS STUDY ADDRESS?
 How can the population PKs of bedaquiline’s M2
metabolite be described in patients with MDR-TB?  How
does body weight and albumin concentration change after
initiation of anti-TB treatment and how does this impact
bedaquiline and M2 PKs?  What other covariates are
relevant for bedaquiline and/or M2 PKs?
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 The first characterization of M2 population PKs in
patients with MDR-TB.  Knowledge of the dynamics of
body weight and albumin over time after the start of anti-
TB treatment, which should be considered also for other
anti-TB drugs.  Characterization of the impact of cova-
riates on bedaquiline and M2 PKs.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS?
 The model enables exposure-response analysis for
bedaquiline’s effect on the TB infection and M2’s sus-
pected effect on QT-prolongation. Once exposure-
response relationships are established, dosing can be
optimized.
Bedaquiline has recently gained regulatory approval for
treatment of multidrug-resistant tuberculosis (MDR-TB)
based on results from phase II trials.1 Although much
remains to be shown regarding its safety and optimal use,2
the approval of bedaquiline is a very welcome event as
new treatment options are urgently needed. During the pre-
ceding 4 decades, no new classes of anti-tuberculosis (TB)
drugs were introduced and, in the same time period, the
alarming increase of drug-resistant TB strains took off. In
the year 2000, the estimated number of new MDR-TB
cases, defined as cases with Mycobacterium tuberculosis
strains resistant to at least rifampicin and isoniazid, impor-
tant components of the old but efficient first-line TB treat-
ment, was 273,000 globally,3 whereas, in 2014, it had
increased to 480,000.4 The current second-line TB therapy
used for MDR-TB is exceedingly long (commonly 18–24
months), has serious side effects,5 and unacceptable low
success rates; on average 50%.4
Bedaquiline is a diarylquinoline with a novel mechanism
of action inhibiting the mycobacterial adenosine triphos-
phate synthase and thereby disrupting the bacteria’s energy
metabolism.6,7 Phase II trials with bedaquiline added to a
background regimen of second-line TB drugs demonstrated
that bedaquiline significantly decreased the time to sputum
culture conversion and increased the proportion of patients
with negative cultures at 120 weeks.8–10 Safety concerns
regarding bedaquiline include its ability to cause moderate
QT-prolongation and the unexplained increase in late mor-
tality observed in one randomized phase II trial.1,11 The
approved regimen of bedaquiline consists of a 2-week load-
ing phase of 400 mg daily, and thereafter 200 mg three
times weekly until week 24.12
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The pharmacokinetic (PK) profile of bedaquiline is char-
acterized by extensive tissue distribution and an extremely
long terminal half-life of >5 months.13 Bedaquiline primarily
undergoes N-demethylation catalyzed by the cytochrome
P450 (CYP) 3A4 enzyme and forms a three to sixfold less
active metabolite, M2.10,14 M2 circulates at 10-fold lower
concentrations than bedaquiline but may have a higher risk
of causing toxicity and is, therefore, important to
describe.15–17 In preclinical tests, M2 was found to be a
stronger inducer of phospholipidosis and more cytotoxic
than bedaquiline.15 M2 concentrations have also been
associated with QT-prolongation.17 M2 is further N-
demethylated, likely primarily by the same enzyme.10,18
The renal excretion of bedaquiline has been shown to be
negligible, but fecal excretion occurs.13 Both bedaquiline
and M2 are highly protein bound, >99.9% and >99.7%,
respectively.13
An overview of existing knowledge on bedaquiline PKs
was recently published,13 and two population PK models
are currently available. The first model was developed to
characterize the interaction effect of the antiretroviral efavir-
enz on bedaquiline, M2, and M3 PKs based on single-dose
data from a phase I trial in healthy volunteers,18 and the
same model has also been applied for characterization of
other drug-drug interactions.19,20 The second model
describes bedaquiline PKs and was developed on com-
bined data from a large number of phase I and II trials,
including several drug formulations, healthy volunteers, and
patients with drug-sensitive-TB, and MDR-TB, and multiple
centers globally.21 The exposure-response relationships for
bedaquiline and M2 are generally poorly characterized. The
aim of the current analysis was to alleviate the lack of a
population PK model describing both bedaquiline and M2 in
patients with MDR-TB during long-term treatment, and to
perform a comprehensive covariate analysis specifically
within the MDR-TB patient population intended to use
bedaquiline. The model should be applicable for PK-
pharmacodynamic analyses of efficacy as well as safety,
and for clinical trial simulations of pediatric studies.
METHODS
Patient population and study design
Data were obtained from two phase IIb studies called C208
and C209 (TMC207-C208, ClinicalTrials.gov number
NCT00449644 and TMC207-C209, ClinicalTrials.gov num-
ber NCT00910871) shared to the PreDiCT-TB consortium.
The bedaquiline data from both studies were included in
the database used in the development of one of the pub-
lished bedaquiline PK models,21 and the treatment out-
comes have been presented elsewhere.8,9,22
C208 was a randomized, double-blind, placebo-controlled
study enrolling newly diagnosed patients with pulmonary
MDR-TB between 18 and 65 years of age. Subjects with
human immunodeficiency virus (HIV) infection having a
CD41 count bellow 300 cells/ml or receiving antiretroviral
therapy were excluded from the study. The study was divid-
ed into two groups encompassing 8 weeks (stage 1) or 24
weeks (stage 2) of interventional treatment. Patients were
randomized to receive either bedaquiline or placebo on top
of a preferred background regimen of five second-line anti-
TB drugs.9 Bedaquiline was administered orally and the
regimen consisted of 400 mg daily during the first 2 weeks,
thereafter 200 mg three times per week. Blood samples for
full PK profiles (predose and 1, 3, 5, 6, 8, 12, and 24 hours
after dose) were drawn after the last doses of weeks 2 and
8 for all patients in stage 1 and after the last doses of
weeks 2 and 24 for a subset of patients in stage 2. Addi-
tional predose samples were collected five to seven times
throughout the treatment period and samples were also col-
lected during the follow-up period, which lasted 96 weeks
after the end of bedaquiline/placebo treatment. Body weight
and albumin concentrations were measured every second
week during the treatment period, every fourth week until
week 36 after the start of treatment, and thereafter every
third month until the end of the follow-up period.
C209 was an open-label study enrolling newly diagnosed
adult patients with pulmonary MDR-TB or extensively drug-
resistant-TB. Subjects with HIV infection were allowed to
participate if their CD41 count was above 250 cells/ml and
met the requirement regarding allowed antiretroviral treat-
ment specified in the protocol. The patients received 24
weeks of bedaquiline treatment on top of an individualized
background and with the same dosing regimen as in C208.
The patients could have started the background therapy
earlier than the bedaquiline treatment. Blood samples were
drawn 1 hour before intake of bedaquiline at weeks 2, 12,
and 24 of treatment. Body weight and albumin concentra-
tions were measured at the start of treatment, at weeks 4,
12, and 24 after the start of treatment, and every third
month during the 96-week follow-up period.
Patients were asked to take their medication together
with water after breakfast and intake was supervised with
directly observed therapy, according to national guidelines.
Concomitant medications with potential to induce or inhibit
CYP3A4 were not permitted. The trials were conducted in
accordance with the Good Clinical Practice standards and
received ethical approval from the appropriate local
authorities.
Chemical analysis
Bedaquiline and M2 were quantified with a validated liquid
chromatography-tandem mass spectrometry methodology.21
The lower limit of quantification was 1 ng/mL for both beda-
quiline and M2.
PK modeling
Nonlinear mixed-effects models consisting of structural
components describing the typical PK characteristics and
stochastic components describing the random variability in
the population were utilized. Bedaquiline and M2 PK obser-
vations from C208 and C209 were modeled simultaneously.
The observed concentrations were converted to molar units
and log-transformed. To describe bedaquiline absorption,
the following models were evaluated: a dynamic transit-
compartment model,23 a model with dual zero-order input
function,21 and models with one or two transit compart-
ments. Structural models considered for disposition were
two, three, and four-compartment models for bedaquiline
and one and two-compartment models for M2. The typical
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values for bioavailability (F) and the fraction of bedaquiline
metabolized to M2 (fm) were fixed to one, hence, the dispo-
sition parameters estimated were relative to F for bedaqui-
line and relative to F times fm for M2. The stochastic model
included between-subject variability (BSV), between-
occasion variability, and residual variability. Individual
parameters were assumed to be log-normally distributed.
Modeling of body weight and albumin concentrations
Models of the time-course of body weight and albumin
were developed based on the observed data. Evaluated
functions included linear and sigmoid maximum effect mod-
els, a previously described semimechanistic model (only for
albumin),24 and a self-limiting logistic model. The models of
body weight and albumin were developed separately from
the structural PK model, but fitted simultaneously with the
PK model in the covariate analysis.
Covariate selection
Seven covariates were considered in the covariate analysis:
body weight, age, race, HIV status, sex, TB type, and albu-
min. The covariate model-building process included a
mechanism-based evaluation and an exploratory search.
The mechanism-based process tested expected effects of
(time-varying) body weight (allometric scaling25) and albu-
min (for protein binding and hepatic function) expressed as
power-function models. Simultaneous incorporation was
necessary due to the observed positive correlation between
body weight and albumin concentrations at baseline and
the opposite effect these covariates are expected to have
on disposition parameters. The theory and assumptions for
the link between albumin concentrations and protein bind-
ing is explained in detail in the Supplementary Material.
The exploratory search included covariate-parameter
relationships earlier detected for bedaquiline,21 and scientif-
ically plausible effects of age, HIV, and TB type. The deci-
sion to include a relationship was based on the likelihood
ratio test. The additional exploratory search started with
univariate analysis, after which relationships were added in
a stepwise manner starting from the one with the largest
impact and tested both with the same and separate effects
on bedaquiline and M2 parameters. Continuous covariates
were normalized to the median value in the population and
included in a linear manner using Eq. 1.
h1i5h13 11 covmed2covið Þ3h2ð Þ (1)
Model selection and evaluation
A significance level of P<0.01 in a likelihood ratio test was
used to accept model extensions. Evaluation of models
was based on scientific plausibility and graphical analysis
of goodness-of-fit plots. The goodness-of-fit plots used
included population and individual predictions vs. observa-
tions, conditional weighted residuals vs. time after dose
and vs. individual predictions as well as visual predictive
checks (1,000 simulations). Prediction and variability cor-
rected visual predictive checks were used when needed.26
Precision in parameter estimates was obtained with the
sampling importance resampling (SIR) procedure27–29
(details are provided in the Supplementary Material).
Software
The pharmacometric analysis was carried out with the first-
order conditional estimation method with interaction in the
software NONMEM 7.3,30 aided by functionalities imple-
mented in PsN.31 Graphical analysis was conducted with
Xpose4.32 Pirana was used for documentation of the devel-
opment process and as an interface between the above-
mentioned programs.33
RESULTS
Data and structural PK model
Data from 335 patients (23 from study C208 stage 1, 79
from study C208 stage 2, and 233 from study C209) were
included in the analysis. The total number of PK observa-
tions was 2,843 for bedaquiline and 2,873 for M2. Ten of
the 335 patients were missing PK observations. There were
<0.6% of PK observations below the limit of quantification
for each compound, which were excluded from the analy-
sis. Demographic information per study is summarized in
Table 1.
The final structural model (Supplementary Figure S1)
included three compartments for bedaquiline and one for
M2. The data did not show apparent dual absorption peaks,
hence, the simpler absorption model included two transit
compartments was used. A 6-hour upper limit for the time
to 90% completion of absorption was used to avoid implau-
sible long delay times, as initially estimated with the dynam-
ic transit absorption model. The limit was based on the
Table 1 Summary of demographic information collected at start of study, if
not otherwise mentioned, presented as the median (range) or number of
subjects (%)
Study C208 (n5 102) C209 (n5 233)
Age, years 31 (18–63) 32 (18–68)
Female sex 31 (31.6) 81 (35.7)
HIV coinfection 11 (11.5) 11 (5.0)
Weight, kg
Day before start of treatment 55 (37–81) 57 (30–113)
Last observation, median week 120 59 (29–92) 60 (27–125)
Albumin, g/dL
Day before start of treatment 3.4 (1.5–4.9) 3.8 (1.7–4.9)
Last observation, median week 120 3.9 (1.3–4.7) 4.1 (1.1–5.3)
TB type
DS 3 (2.94) 3 (1.3)
MDR 70 (68.6) 90 (38.6)
Pre-XDR 17 (16.7%) 43 (18.5%)
XDR 3 (2.9%) 37 (15.9%)
Missing 9 (8.8%) 60 (25.8%)
Race
White 8 (7.8) 56 (24.0)
Black 40 (39.2) 74 (31.8)
Hispanic 13 (12.7) 0 (0)
Asian 9 (8.8) 89 (38.2)
Other 28 (27.5) 8 (3.4)
Missing 4 (3.9) 6 (2.6)
TB, tuberculosis; DS, drug sensitive; HIV, human immunodeficiency virus;
MDR, multidrug resistant; Pre-XDR, Pre-extensively drug resistant; XDR,
extensively drug resistant.
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typical small intestine transit time.34 Estimated parameters
were the mean absorption time (MAT; i.e., typical time to
90% complete absorption) and the fraction of MAT, which
consisted of delay in the transit compartments or first-order
absorption, respectively (see model code in Supplementa-
ry Material). Correlations were significant between the
BSV in the clearances (CLs) and in the residual variabilities
of bedaquiline and M2, respectively. Residual variability
was additive on log-scale and a positive correlation
between bedaquiline and M2 observations at the same
timepoint (same blood sample) was significant.
Model of body weight and albumin concentrations
A total of 5,438 body weight observations and 4,684 albu-
min concentrations obtained from screening to last follow-
up visit were available from both studies (except stage 1 in
study C208 in which body weight observations were only
available from baseline). A linear model was found suffi-
cient to describe body weights. Albumin was best fitted with
the self-limiting logistic model (Eq. 2, where A(t) is the time
dependent albumin concentrations, ASS is the steady-state
concentrations of albumin expected after treatment and
T1=2return is the half-life of the return towards ASS).
dA tð Þ
dt
5
ln 2ð Þ
T 1=2return
A tð Þ 12 A tð ÞÞ
Ass

(2)
BSV was significant on all parameters. The description of
the outer data percentiles was improved when using Box-
Cox distributions35 of the BSV for parameters describing
albumin at start of treatment (A0) and at steady state (Ass)
as well as body weight at 120 weeks after the start of treat-
ment (WT120). Correlations were found between all BSV
parameters of the two models. Proportional residual error
models were used for both weight and albumin. Estimated
model parameters with associated precision are given in
Table 2. Selected goodness-of-fit plots are presented in
Figures 1 and 2. Figure 1 displays a visual predictive
check of the final models. Figure 2 shows individual fits for
three patients who were selected to reflect the diversity of
encountered time profiles.
Covariate model
The mechanism-guided covariate modeling resulted in
inclusion of the following relationships: (i) time-varying pre-
dicted body weight on CLs and volumes using allometric
scaling with estimated coefficients for CLs and coefficients
fixed to one for volumes; (ii) time-varying predicted albumin
concentrations on all disposition parameters using power
models with coefficient fixed to one; and (iii) change in
time-varying predicted albumin concentrations as a marker
of hepatic function on bedaquiline and M2 CL and fm. The
total difference in objective function value (DOFV) after
inclusion of these relationships with two parameters fixed to
theoretical values and two estimated parameters was 2320
points. The exploratory covariate search detected patients
of black race to have a significantly higher CL of bedaqui-
line and M2 (DOFV 298.7), and increasing age giving a lin-
ear decrease in CL of bedaquiline and M2 (DOFV 222.9).
Covariate model code is available in the Supplementary
Material. Adding effects of sex on volume, black race on F
or HIV or TB type on CL or F did not improve the fit signifi-
cantly. The included covariates jointly decreased the BSV
in apparent bedaquiline and M2 CL from 62% to 48% and
72% to 60%. Parameter estimates and their 95% confi-
dence intervals (CIs) for the final model are listed in Table 3.
The estimated typical MAT and fraction of MAT which con-
sisted of delay in the transit compartments corresponds to a
first-order absorption rate of 1.1 h21 and mean transit time of
1.9 hours. The model’s good fit to the data is demonstrated
Table 2 Final parameters for the model of body weight and albumin concentrations over time on anti-TB treatment in MDR-TB patients fitted simultaneously
with the PKs
Fixed effects Estimate (SIR 95% CI)
A0, g/dL 3.65 (3.61–3.7)
Ass, g/dL 4.04 (4.01–4.07)
T1=2return, weeks 20.4 (17.7–23)
WT0, kg 56.6 (55.8–57.5)
WT120, kg 62.6 (61.4–63.8)
Shape Box-Cox BSV A0 22.44 (22.70 to 22.17)
Shape Box-Cox BSV ASS 25.38 (26.08 to 24.71)
Shape Box-Cox BSV WT120 20.42 (20.64 to 20.19)
Random effects (CV [%] and
correlations [%]) Estimate (SIR 95% CI)
BSV A0 16.0 (15.3–16.7)
BSV ASS 50.3 (44.9–56.3) 9.9 (9.4–10.4)
BSV R 252.7 (260.4 to 244.1) 9.1 (3.4–13.9) 129 (112–156)
BSV WT0 36.1 (32.3–40.7) 24.7 (19.7–29.0) 218.7 (224.5 to 210.2) 20.7 (19.9–21.6)
BSV WT120 15.8 (12.4–20.8) 29.7 (24.6–36.3) 21.0 (24.8 to 2.3) 81.1 (77.5–84.0) 22.5 (21.6–23.6)
Prop. error albumin 7.08 (6.89–7.29)
Prop. error body weight 3.47 (3.30–3.47)
A0 and Ass, albumin concentration at start of treatment and steady state; BSV, between subject variability; CI, confidence interval; CV, coefficient of variance;
MDR, multidrug-resistant; PKs, pharmacokinetics; prop. error, proportional residual error; SIR, sampling importance resampling; T1=2return, half-life of the return
toward ASS; TB, tuberculosis; WT0 and WT120, body weight at start of treatment and 120 weeks after start of treatment.
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for different time periods in the visual predictive checks pre-
sented in Figure 3.
DISCUSSION
A population model describing bedaquiline and M2 PKs,
body weights, and albumin concentrations simultaneously
in patients with MDR-TB was successfully developed. PKs
in patients with MDR-TB is expected to differ from PKs in
healthy volunteers,21 and this is the first model developed
on patient data that also characterizes M2 PKs. M2 is less
active than bedaquiline in vitro and not expected to contrib-
ute meaningfully to the clinical efficacy on M. tuberculosis,
but remains important due to safety concerns. Besides the
interest in M2 PKs itself, inclusion of metabolite data has
the advantages of improving the ability to characterize
bedaquiline PKs, including its covariate relations, with good
precision.36
The measurements of plasma albumin concentration and
body weight over time on treatment showed that both gradu-
ally changed over the course of treatment, typically increas-
ing by around 10% between baseline and the end of the
study (Figure 1). In several individuals, body weight
changed by >10 kg and albumin concentrations increased
by >50% over the 24 weeks of bedaquiline treatment. It has
previously been observed that albumin concentrations in
patients with pulmonary TB are lower compared with healthy
controls,37 and that albumin concentrations increase over time
on treatment,38 likely reflecting a general improvement of
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Figure 1 Visual predictive check showing the 2.5th, 50th, and 97.5th percentiles (lines) of observed albumin concentration and body
weights (dots) and the 95% confidence intervals (shaded areas) of the same percentiles from model-simulated data.
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Figure 2 Examples of individual fits from three patients with distinctly different profiles: typical increase (ID1), less common decrease
(ID2), or relatively constant (ID3) albumin concentrations.
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health when the TB infection is cleared. The improved health
status may also explain the weight increase. As both bedaqui-
line and M2 are highly protein bound (>99.9% and 99.7%,
respectively13), changes in unbound fraction in plasma are
expected to impact the PKs disposition properties because
the compounds’ extraction ratio is low and the volume of
distribution is large.39 Scaling disposition parameters with rela-
tive unbound fraction in plasma (calculated based on individu-
ally predicted time-varying albumin concentrations and the
typical albumin concentration at steady state) improved the fit
of the model, which points toward the fact that albumin is
important for protein binding. The impact of albumin concen-
trations on bedaquiline CL and central volume of distribution
(V) is demonstrated in Figure 4. Varying protein binding is
rarely of clinical relevance because the unbound plasma con-
centration, which usually generates the pharmacological
effect, is independent of unbound fraction in plasma,39 hence,
dose adjustments based on albumin concentrations would not
need to be considered. However, due to the complex patho-
physiology of TB and bedaquiline’s extensive distribution it is
difficult to predict the relationship between plasma concentra-
tions and the unbound concentration at the site(s) of action.
Nonetheless, the unbound fraction in plasma does impact PK
parameters under given conditions,39 and must, therefore, be
accounted for to describe observed concentration-time profiles
and accurately explain variability. For example, typical CL
(and all other disposition parameters) is predicted to be 3.3
times higher in a patient with the lowest observed albumin
concentration at the start of treatment compared to a patient
with the highest observed concentration.
A previous analysis did not find any effects of body size
on bedaquiline disposition,21 which may be due to (i) the
positive correlation between body weight and albumin (36%
and 30% at the start and end of the treatment period);
(ii) the use of baseline instead of time-varying values; and
(iii) the absence of metabolite data. With weight included in
the model, the previously observed effect of sex on volume
of distribution was not needed. The coefficient for allometric
scaling of volumes with body weight were found to not differ
significantly from the theoretical value of one, whereas the
coefficient for scaling of CLs were significantly lower than
the theoretical value of 0.75. The characterization of the
effect of body weight on PKs was important to enable use
of the model in clinical trial simulations of future pediatric
studies. Uncertainty in the estimated coefficient and the
potential correlations with disease recovery should be con-
sidered in such simulations and in calculations of pediatric
doses.
Individual changes in albumin concentrations were found
to describe changes in individual CL of bedaquiline, M2,
and fm over time. It can be hypothesized that the hepatic
capacity to metabolize bedaquiline and M2 is increasing as
the general health status of the patients increase over time
on treatment. Improved hepatic function is reflected in the
increased albumin concentrations because albumin is syn-
thesized in the liver,24 and leads to increased CLs. Howev-
er, fm is also decreasing, which may then be explained by
the fact that the increased hepatic capacity leads to a larg-
er fraction sequential metabolism (i.e., bedaquiline metabo-
lized to M2 and M2 directly metabolized to M3 without
exiting the hepatocyte), and thereby decreasing fm.
The mechanism-based parameter-covariate relationships
distinctly improved the description of observed bedaquiline
and M2 concentrations (DOFV 2320). The pattern of
changes over time in different parameters is complex as
weight and albumin are positively correlated but may trigger
Table 3 Parameter estimates with uncertainty of the final PK model of beda-
quiline and M2 including covariates and estimated simultaneously with the
albumin-weight model
Fixed effects Estimate (SIR 95% CI)
MAT, fraction of 6 hours 0.66 (0.62–0.71)
FR 0.47 (0.42–0.54)
CL/F, L/h 2.62 (2.49–2.75)
V/F, L/70 kg 198 (184–215)
Q1/F, L/h 3.66 (3.35–3.97)
VP1/F, L/70 kg 8,550 (7,940–9,230)
Q2/F, L/h 7.34 (6.8–7.84)
VP2/F, L/70 kg 2,690 (2,390–2,980)
CLM2/(F3 fm), L/h 10.0 (9.5–10.6)
VM2/(F3 fm), L/70 kg 2,200 (2,060–2,370)
Allometric scaling clearancesb 0.18 (0.07–0.29)
Time varying effect of protein binding
on dispositionb
1 Fix
Individual time varying effect of albumin
CL/CLM2/fbm
1.64 (1.46–1.81)
Effect of black race on CL/CM2b 0.84 (0.70–0.99)
Age effect on CL/CLM2b 0.0088 (0.0074–0.0114)
Random effects Estimate (SIR 95% CI)
BOVa F, CV% 19.7 (16.0–24.8)
BOVa MAT, CV% 148 (101–265)
BSV F, CV% 28.9 (24.5–32.3)
BSV CL, CV% 40.7 (37.2–45.4)
BSV CLM2, CV% 48.6 (44.1–52.8)
Correlation BSV CL-CLM2, % 75.0 (69.5–80.9)
BSV V, CV% 43.3 (35.0–52.5)
BSV Q1, CV% 44.5 (34.9–55.0)
BSV VM2, CV% 40.2 (35.6–48.2)
BSV RUVBDQ, CV% 23.5 (19.5–27.6)
BSV RUVM2, CV% 23.2 (19.9–26.7)
Correlation BSV RUVBDQ-RUVM2, % 55.6 (32.0–77.8)
Proportional residual error BDQ, CV% 23.1 (22.0–24.2)
Proportional residual error M2, CV% 19.3 (18.2–20.4)
Correlation BDQ-M2 residual error, % 43.3 (38.0–47.5)
The parameters listed are applicable for a non-black patient of 70 kg with
median age (32 years) and albumin concentrations as typical at steady state
(4.04 g/dL). BDQ, bedaquiline; BOV, between occasion variability; BSV,
between subject variability; CI, confidence interval; CL, clearance; CV, coef-
ficient of variation calculated with sqrt(exp(OMEGA)21) where OMEGA is
the estimated variance; F, bioavailability; fm, fraction bedaquiline metabolized
to M2; FR, fraction of MAT which is delay in the transit compartments; MAT,
mean absorption time; PK, pharmacokinetic; Q, intercompartmental clear-
ance; RUV, residual unexplained variability; SIR, sampling importance
resampling; V, volume of distribution central compartment; VP, volume of dis-
tribution peripheral compartment.
aStudy C208 was divided in two occasions; one for each period of rich PK
sampling. Study C209, in which only single samples were drawn, was
regarded as one occasion.
bSee parametrization of covariate effects in the model code provided in the
Supplementary Material.
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Figure 3 Prediction and variability corrected visual predictive checks showing the 2.5th, 50th, and 97.5th percentiles (lines) for
observed bedaquiline (BDQ) and M2 concentrations and the 95% confidence intervals (shaded areas) of the same percentiles from
model-simulated data over time after the start of treatment (upper panel 0–24 weeks and middle panel 24–96 weeks) and over time
after dose (lower panel).
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opposite effects, as illustrated in Supplementary Figure S2,
for the typical change in body weight and albumin concentra-
tions. Specific individual weight and albumin dynamics yields
different total effects on the PK parameters, which can be
notably stronger than the typical or even go in the opposite
direction.
Increasing age was found to decrease CL of bedaquiline
and M2 linearly with 0.9% (95% CI5 0.8–1.0%) per year
and patients of black race were estimated to have 84%
(95% CI575–94%) higher typical CL of bedaquiline and
M2 compared to non-black subjects. Estimating separate
effects for bedaquiline and M2 CL did not improve the
description, which is expected because the main CL path is
thought to be the same. The age effect should not be
extrapolated outside the currently investigated age range.
For pediatric studies, we instead suggest to account for
age with previously described maturation functions for
CYP3A4.40 The activity of CYP3A4, which is the main
enzyme responsible for bedaquiline and M2 metabolism, is
known to vary substantially and relationships with age and
genetic polymorphisms has been reported.41 The effect of
black race on CL estimated here (184%) is slightly stron-
ger than the previously reported effect (152%).21 The
physiological rationale for this effect is unclear and should,
therefore, be interpreted with caution. It should be noted
that the race categories overlap with study site and all but
two of the black patients were included at South African
sites. It has been suggested that the effect could be linked
to regional differences in diet changing the bioavailability,
which could be picked up as an effect on apparent CL.13
However, this hypothesis was not supported by our work
since assigning the effect of black race to F instead of CL
resulted in a significantly worse data fit. Another potential
explanation could be regional differences in genetic make-
up. Substantial genetic variation in CYP3A4 has been
documented; however, there are, to our knowledge, no
CYP3A4 polymorphisms with significant impact on metabo-
lizing efficiency described.41
The estimates of apparent CL and central V for bedaqui-
line were similar to earlier presented estimates obtained
partly from the same data (2.62 L/h and 198 L compared to
2.78 L/h and 164 L21). The extensive distribution and long
terminal half-life of both bedaquiline and M2 were con-
firmed and are thought to be related to the cationic amphi-
philic properties of the compounds, causing them to bind to
intracellular structures and thereby accumulate in tissues.13
Our structural bedaquiline model is more parsimonious
(one distribution compartment less and simpler absorption
model) compared to the previously presented model and
describes the bedaquiline observations better (DOFV
2456). The improvements could be achieved by narrowing
the scope to only data from patients with TB on treatment
with the approved formulation, and the inclusion of time-
varying covariates. The model predicts both bedaquiline
and M2 concentrations to be highest in the end of the initial
2 weeks with daily dosing of 400 mg. When the thrice
weekly dosing of 200 mg is initialized, the concentrations
drops and thereafter a slow accumulation occurs through-
out the treatment period but without reaching actual steady
state levels. A summary of individual model-predicted
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Figure 4 Illustration of covariate relationships included on bedaquiline (BDQ) clearance (CL) and central volume of distribution (V) in
the final model. For CL the solid and dotted lines represent the typical values for non-black and black patients, respectively. For V, the
solid line is the typical value. The shaded areas are the 95% confidence interval of the interindividual variability. The lines at the bottom
of the graphs represent observed covariate values at the start of treatment.
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exposures of bedaquiline and M2 at different timepoints is
provided in Supplementary Table S3. Treatment with beda-
quiline may cause QT-prolongation,9,13 and a positive relation-
ship between M2 concentrations and QT-prolongation has
been detected.17 Because QT-prolongation is commonly
regarded to be a direct effect, we recommend future studies
investigating the link between bedaquiline and/or M2 exposure
and QT-prolongation to focus on the time-period when the
concentrations are expected to be the highest (i.e., by the
end of the second week of daily dosing 400 mg).
The limitations of this model include the extremely long
run-times for parameter estimation due to the complex dif-
ferential equation system and the many observations over
a long time-period. The estimated increase in albumin and
weight after the start of treatment might be biased down-
ward by the fact that part of the patients in study C209
had started the background therapy earlier than they
started bedaquiline therapy, which the model did not
account for. Making full use of the model in analysis of oth-
er datasets may be limited by the lack of observations of
albumin concentrations and weights over time on treatment
because this is not routinely recorded. However, since
these covariates were modeled and correlations estimated,
the full model can be applied as long as there is at least
one observation of either weight or albumin concentration
per individual. The usefulness of individual model-derived
secondary PK metrics for exposure-response analysis in
this dataset might be compromised by the fact that all
patients had the same bedaquiline dosing regimen; result-
ing in a relatively small interindividual spread in the expo-
sures. Another limitation is the unclear physiological
rationale for the effect of black race, making interpretation
difficult.
In conclusion, a population model describing the accumu-
lation of bedaquiline and M2 during the 24-week treatment
period as well as the slow elimination from the body after
the end of treatment was successfully developed. The mod-
el also describes the dynamic changes of important charac-
teristics, such as body weight and albumin concentrations
in patients with MDR-TB. The model can be used in clinical
trial simulations for pediatric trials with bedaquiline, in stud-
ies designed to confirm in patients the PK drug-drug inter-
actions quantified in healthy volunteers,42 and in model-based
PK-pharmacodynamic analysis aiming at learning more about
the concentration-response relationships for bedaquiline and
M2.43
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